Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave the company a Strong Buy Rating and a $9 Price...
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
KRAS, one of the most mutated oncogenes across cancers, drives aggressive and treatment-resistant tumors. Silexion’s latest data highlights SIL-204’s ability to enhance first-line therapies...
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion...
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ:...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.19 | 177.611940299 | 0.67 | 3.45 | 0.575 | 116153094 | 2.38082127 | CS |
4 | -0.18 | -8.82352941176 | 2.04 | 3.45 | 0.575 | 35750209 | 2.33628635 | CS |
12 | -0.57 | -23.4567901235 | 2.43 | 4.23 | 0.575 | 15356828 | 2.51609292 | CS |
26 | -39.27 | -95.4777534646 | 41.13 | 41.85 | 0.575 | 8993434 | 3.32469067 | CS |
52 | -39.27 | -95.4777534646 | 41.13 | 41.85 | 0.575 | 8993434 | 3.32469067 | CS |
156 | -39.27 | -95.4777534646 | 41.13 | 41.85 | 0.575 | 8993434 | 3.32469067 | CS |
260 | -39.27 | -95.4777534646 | 41.13 | 41.85 | 0.575 | 8993434 | 3.32469067 | CS |
Symbole | Prix | Vol. |
---|---|---|
TCTMTCTM Kids IT Education Inc | US$ 0,764 (321,87%) | 731,1M |
NVDANVIDIA Corporation | US$ 120,07 (-3,67%) | 388,5M |
RIMEAlgorhythm Holdings Inc | US$ 0,02565 (5,12%) | 341,8M |
CLEUChina Liberal Education Holdings Ltd | US$ 0,1938 (30,77%) | 237,15M |
BHATBlue Hat Interactive Entertainment Technology | US$ 0,0355 (-11,25%) | 236,44M |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales